English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

HIV infection is one of the major global public health problem. Currently, among the specialists, an estimated 33 million people are infected with HIV worldwide. At present, six main classes of antiretroviral drugs exist, and almost all of them are used in antiretroviral therapy regimen in treatment-experienced as well as treatment-naive patients. Protein inhibitors are selective inhibitors of the cleavage of HIV-encoded gag-pol polyproteins. Darunavir, previously known as TMC-114, is a new, second-generation PI. Darunavir has high potency, genetic barrier and very good clinical and metabolic tolerance. In twice-daily dose darunavir is used as a rescue therapy in treatment-experienced patients. However, after ARTEMIS study, it was recently approved in first-line antiretroviral therapy for treatment-naïve HIV-infected patients.

Boosted darunavir as a new therapeutic option for treatment-naive HIV-infected patients